New CEO Jake Leach said the company plans a trial readout in mid-2026 to support coverage of its glucose sensors in Type 2 users who don’t take insulin.
On its earnings calls to investors, Sayer has made no secret about Dexcom’s aspirations to widen its total addressable market by eventually marketing its CGMs to people with Type 2 diabetes. This ...
Despite potential headwinds to the medical supplies market, continuous glucose monitors (CGMs) remain a good opportunity, but providers must take a hard look at how well they think ...
This weekend saw the kickoff of the American Diabetes Association’s 78th annual conference, and with it a slew of new data from diabetes management players. The meeting included presentation on ...
While patients living with diabetes have been familiar with continuous glucose monitors, and their new advancements, for years, these devices now have a place in the mainstream health technology ...
BURNABY, British Columbia--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), a global leader in glucose biosensing technology, is proud to announce that the Dexcom G7 Continuous Glucose Monitoring (CGM) ...
I saw a patient a few years ago who had come to me because he had been using a continuous glucose monitor (CGM), despite not having diabetes, and was worried about what he called "glucose spikes" ...
The researchers found that in those without diabetes, continuous glucose monitors are not a substitute for HbA1c. HealthDay News — Continuous glucose monitors (CGMs) do not accurately reflect blood ...
The very idea that one day you might slip into the category of being diabetic is mind-boggling. India, after all, has already earned the dubious title of the diabetes capital of the world, with over ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results